SCHEMBL923249

SCHEMBL923249

N#Cc1cccc(Nc2nc(C3CC3)nc3sc4c(c23)CCCC4)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
RAB9A P51151 2/20 0.50
PTGS2 P35354 4/20 0.48
MKNK1 Q9BUB5 4/20 0.47
EGFR P00533 2/20 0.47
MAPK1 P28482 2/20 0.44
LMNA P02545 2/20 0.44
RAF1 P04049 1/20 0.44
HTT P42858 1/20 0.44
GAA P10253 2/20 0.44
POLB P06746 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923161 0.87 MAPT (0.54) MAPTRAB9APTGS2MKNK1EGFR
SCHEMBL924310 0.85 MAPT (0.69) MAPTRAB9APTGS2MKNK1EGFR
SCHEMBL922804 0.85 MKNK1 (0.66) MAPTRAB9APTGS2MKNK1EGFR
SCHEMBL922886 0.82 MAPT (0.50) MAPTRAB9APTGS2MKNK1EGFR
SCHEMBL923231 0.82 MKNK1 (0.67) MAPTRAB9APTGS2MKNK1EGFR
SCHEMBL923542 0.81 PTGS2 (0.60) MAPTRAB9APTGS2MKNK1EGFR
SCHEMBL923360 0.81 MKNK1 (0.71) MAPTMKNK1EGFRMAPK1LMNA
SCHEMBL30283308 0.67 SYK (0.46) EGFRPOLBSMN1; SMN2NPSR1
SCHEMBL28994613 0.67 SYK (0.46) EGFRPOLBSMN1; SMN2NPSR1
SCHEMBL924123 0.67 MKNK1 (0.77) MAPTMKNK1EGFRMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US claimed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US claimed
EP-2257554-A1 TRICYCLIC BENZOÝ4,5¨THIENO-Ý2,3-D¨PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE Vichem Chemie Kutató KFT (HU) 2010-12-08 EP claimed
WO-2009104026-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATÓ KFT (HU) 2009-08-27 WO claimed
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US disclosed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE TYMS, TYMP, DPYD MAPT 3085/4885RAB9A 2986/4885PTGS2 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.